Investments
1
Want to inform investors similar to Jianmin Pharmaceuticals about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Jianmin Pharmaceuticals News
Mar 4, 2016
San Antonio-based Fe3 Medical , a company developing a transdermal patch to help patients with iron-deficiency anemia, has raised $11M in a funding round, the company said this week. The SEries B funding came from Jianmin Pharmaceuticals, HG Capital and PingAn Ventures, along with InCube Ventures. Fe3 Medical's transdermal patch delivers iron to anemic patients. The company said the funding goes towards clinical trials andregulatory submissions, which are required for both CE Mark and FDA approval. As part of the funding, the company says it has named Mark Sieczkarek as CEO of the company; Sieczkarek led Solta Medical (acquired by Valeant Pharmacuticals), Conceptus (acquired by Bayer Pharmaceuticals), and has served at Bausch & Lomb and Bristol-Myers Squibb, and currently serves as Chairman of NovaBay.
Jianmin Pharmaceuticals Investments
1 Investments
Jianmin Pharmaceuticals has made 1 investments. Their latest investment was in Fe3 Medical as part of their Series B on March 3, 2016.
Jianmin Pharmaceuticals Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/2/2016 | Series B | Fe3 Medical | $11M | Yes | 2 |
Date | 3/2/2016 |
|---|---|
Round | Series B |
Company | Fe3 Medical |
Amount | $11M |
New? | Yes |
Co-Investors | |
Sources | 2 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.